Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$272.64 USD
-4.69 (-1.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $272.59 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALNY 272.64 -4.69(-1.69%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Other News for ALNY
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
SIZE: A Good Mid-Cap ETF, Yet Not The Best
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market Potential
Goldman upgrades Alnylam to Buy ahead of 'fundamental re-rating'
Goldman Sachs gets more bullish on Alnylam, upgrades shares